FDA Lashes Out at Latisse

The Food and Drug Administration recently issued a warning to Allergan Inc., stating that the website for Latisse (a prescription eyelash lengthener) is misleading because it omits and minimizes risks associated with the product.

In a letter dated September 10, the FDA warns that latisse.com misbrands Latisse - in violation of the Federal Food, Drug, and Cosmetic Act - because it does not clearly convey the consequences that may result from use of the drug, which include:

Iris pigmentation
Lid pigmentation
Hair growth outside the treatment area
Intraocular inflammation
Potential for contamination and infections
Absorption by soft contact lenses

To read the letter in its entirety, click here.